Estrella Immunopharma, Inc. (ESLA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は EmeryVille, CA, アメリカ. 現CEOは Cheng Liu.
ESLA を有する IPO日 2021-09-14, に上場 NASDAQ Capital Marke, 時価総額 $73.81M.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
